Genome-wide DNA methylation profiling of blood samples from patients with major depressive disorder: correlation with symptom heterogeneity
Open Access
- 23 April 2025
- journal article
- Published by Canadian Science Publishing in Journal of Psychiatry and Neuroscience
- Vol. 50 (2) , E112-E124
Abstract
Background: Alterations in DNA, such as DNA methylation, may be key molecular events involved in the development of major depressive disorder (MDD). We sought to clarify correlations between DNA methylation profiles and symptom heterogeneity among patients with MDD. Methods: We conducted a genome-wide DNA methylation analysis of blood samples from patients with MDD and controls, using the Infinium MethylationEPIC BeadChip. Results: We analyzed 283 blood samples, including 141 from an initial cohort (69 patients with MDD, 72 controls) and 142 from a second validation cohort (67 patients with MDD, 75 controls). After adjustment for age, sex, and blood cell heterogeneity, DNA methylation status at 2699 CpG sites tended to differ between patients with MDD and controls in both the initial and second cohorts. Hierarchical clustering of patients based on DNA methylation status at these 2699 CpG sites revealed a significant correlation with scores for GRID-Hamilton Depression Rating Scale (GRID-HAMD) items (depressed mood, guilt, early insomnia, middle insomnia, work and activities, psychic anxiety, loss of appetite, general somatic symptoms, and total score), suggesting the feasibility of severity diagnostics based on blood DNA methylation testing. Pathway over-representation analysis revealed that genes whose DNA methylation status was correlated with epigenetic clustering were accumulated in molecular pathways involved in various cellular functions, especially nerve development. For PLEKHD1, STK10, and FOXK1, DNA methylation levels were inversely correlated with expression levels in the Clinical Proteomic Tumor Analysis Consortium database. DNA hypomethylation of PLEKHD1, STK10, and FOXK1 was correlated with higher GRID-HAMD scores in both cohorts. Limitations: Although we performed marker exploration using 2 cohorts including 283 participants, the heterogeneity of the molecular mechanisms operating in MDD might necessitate a larger cohort for establishment of criteria with sufficient diagnostic impact. Conclusion: These findings indicate that the DNA methylation status of specific genes may correlate with the severity of MDD symptoms, and that genome-wide DNA methylation analysis of blood samples would be useful for clarifying the DNA methylation profiles related to symptom heterogeneity.Keywords
This publication has 58 references indexed in Scilit:
- DNA methylation arrays as surrogate measures of cell mixture distributionBMC Bioinformatics, 2012
- Impaired mitochondrial function in psychiatric disordersNature Reviews Neuroscience, 2012
- Enriched pathways for major depressive disorder identified from a genome-wide association studyInternational Journal of Neuropsychopharmacology, 2012
- Genome-Wide Dna Methylation Profiling Using Infinium ® AssayEpigenomics, 2009
- Core symptoms of major depressive disorder: relevance to diagnosis and treatmentDialogues in clinical neuroscience, 2008
- Reliability and validity of Japanese version of the Mini‐International Neuropsychiatric InterviewPsychiatry and Clinical Neurosciences, 2005
- Stk10, a New Member of the Polo-like Kinase Kinase Family Highly Expressed in Hematopoietic TissueJournal of Biological Chemistry, 2003
- Molecular cloning of the human gene STK10 encoding lymphocyte-oriented kinase, and comparative chromosomal mapping of the human, mouse, and rat homologuesImmunogenetics, 1999
- LOK Is a Novel Mouse STE20-like Protein Kinase That Is Expressed Predominantly in LymphocytesJournal of Biological Chemistry, 1997
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960